- CSL Behring's warfarin reversal treatment accepted for US review
- Ruconest meets Phase III endpoint in BLA-determining trial
- Pharming/Santarus make second US attempt with Ruconest
- Dyax adds new Asian deal for Kalbitor to CVie
ONLY 0 DAY LEFT
|Stay close to your market. Renew online now to ensure uninterrupted access to:|
|SCRIP Intelligence's news and expert commentary|
|Market Data and Company Analysis (SCRIP 100, SCRIP Asia 100)|
|The Ask the Analyst Service...and more.|
Please remember to quote your order number and customer number.
You can also renew by calling: +44 (0)20 7017 5540.